[Human papillomavirus nonavalent vaccine. Update 2017]

Area of Science:

• Oncology
• Vaccinology
• Virology

Background:

• Human papillomavirus (HPV) causes 5% of human cancers, including cervical, anal, and oropharyngeal cancers.
• Current bivalent and tetravalent HPV vaccines offer protection against specific HPV types.
• A new nonavalent vaccine targets 9 HPV types responsible for a high percentage of cervical cancers and pre-cancerous lesions.

Purpose of the Study:

• To present scientific evidence supporting the efficacy and clinical value of the new nonavalent HPV vaccine.
• To inform healthcare professionals about the expanded protection offered by the nonavalent vaccine.

Main Methods:

• Clinical program launched in 2006 for the nonavalent vaccine.
• Evaluation of scientific evidence for vaccine efficacy and clinical utility.

Main Results:

• The nonavalent vaccine targets 9 HPV types (6/11/16/18/31/33/45/52/58).
• These targeted types are responsible for 90% of cervical cancers, 82% of high-grade ano-genital pre-cancerous lesions, and 90% of genital warts.

Conclusions:

• The nonavalent HPV vaccine provides broader protection against a wider range of HPV types.
• This enhanced protection offers significant clinical value in preventing HPV-related cancers and lesions.